Navigation Links
MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy

BOTHELL, WA – June 25 – MediQuest Therapeutics, Inc., a specialty pharmaceutical company focused on developing therapies for inflammatory and infectious diseases, today announced the completion of its confirmatory phase III study of Vascana – a topical formulation designed to treat Raynaud’s Disease.

The study met its primary end point and demonstrated statistical significance, with p = 0.008 for the Intent-to-Treat patient population. Typically, a probability value (p) less than .05 is commonly accepted as establishing statistical significance between treatment groups.

“With the conclusion of this clinical study, MediQuest is one step closer to submitting the Vascana New Drug Application to the FDA,” said MediQuest President and CEO Dr. Frederick Dechow. “If approved, Vascana would be the first drug on the market specifically designed to prevent and treat Raynaud’s symptoms, providing clinicians with a needed treatment for patients.”

Vascana has the potential of satisfying an unmet medical need for more than 2 million Americans seeking care for Raynaud’s Disease.

In addition to Vascana, MediQuest’s ongoing developmental efforts have generated a robust pipeline that includes three drug candidates in clinical trials, one at the pre-clinical stage and others at the research stage. The company develops first- and best-in-class topical therapies to treat patients suffering from inflammatory and infectious diseases.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprietary topical delivery system in late-stage clinical trials targeting infectious and inflammatory skin diseases and conditions. The Company’s major efforts are focused on projects targeting Raynaud’s phenomenon, nail psoriasis and actinic keratosis.

In addition to his
'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/30/2014)...   Unique Pizza and Subs Corporation ... a Delaware Corporation, is pleased to announce it ... Corporation ("Larasan"), a nature-based pharmaceutical company that produces and ... Larasan will work with Unique to help distribute ... vast distribution network throughout China ...
(Date:7/30/2014)... July 30, 2014 Silicon Valley Bank, the ... study today that examines the merger, acquisition and ... companies.  According to the annual report based on 2013 ... returns since SVB started tracking the data in 2005. ... Built on solid healthcare M&A activity over the last ...
(Date:7/30/2014)... LONDON , July 30, 2014  Lightlake ... developing addiction treatments based on its expertise in ... a funding commitment from a prominent international research ... a focus on promoting innovative research-based initiatives, including ... a nasal spray for the delivery of naloxone ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... prioritization -, LOUISVILLE, Colo., Dec. 10 ... announced an operational restructuring to align,critical resources ... partner for Replidyne,s late-stage antibiotic, faropenem,medoxomil (faropenem), ... exploring additional corporate development opportunities., The ...
... outcomes for premature babies, FORT WORTH, Texas, ... Now, they are helping improve the care of,premature ... care unit recently implemented the use of the ... results in decreasing the,incidence of chronic lung disease ...
Cached Medicine Technology:Replidyne Provides Strategic Update 2Replidyne Provides Strategic Update 3Replidyne Provides Strategic Update 4Replidyne Provides Strategic Update 5Replidyne Provides Strategic Update 6Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe 2
(Date:7/30/2014)... Daily Gossip indicates in its 60 Second Panic ... attack is a feeling of intense stress and fear, which ... of symptoms that sufferers commonly deal with when panic attacks ... or anxiety. Naturally, panic attacks deeply affect lifestyle; this is ... them. , The 60 Second Panic Solution review promises to ...
(Date:7/30/2014)... and Malaysia (PRWEB) July 30, 2014 ... through education by LTT Global an award winning mobile ... learning on the go since 2004. , MyMobileUni.com’s platform ... quality learning content. MMU has links to the ... organizations, NGOs’ and subject matter experts from all over ...
(Date:7/30/2014)... 2014 Nationally recognized leader in nursing ... since September 2013 has served as president of the ... dean of the College of Nursing at University of ... leadership of the NLN, as the nation's premier voice ... nursing and research institutions in the country. , ...
(Date:7/30/2014)... weeks freshman will begin to pour onto college campuses, each student ... time of growth and the start to something big. Statistically speaking, ... as easy as it looks. Some sources cite as ... once and many will switch two or three times. Each switch ... switching in the later years of college. According to the ...
(Date:7/30/2014)... 30, 2014 Throughout the month of ... free oral cancer screenings. Using a new technological tool ... detect the disease in its early stages. , Oral ... mouth, sinuses, throat and other areas in and around ... Epidemiology, and Ends Results (SEER) program, 30 percent of ...
Breaking Medicine News(10 mins):Health News:60 Second Panic Solution Review Reveals Unique Way to Stop Panic Attacks 2Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 2Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 3Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2
... actress and wife of Brad Pitt has commissioned US ... to celebrate the different stages of her pregnancy. ... her request. About the portrait. ,The painting are ... in Angelinas private collection." ,Bachardy is a ...
... pain's ability to seek attention. ,The ... is distinct from the one involved in cognitive processing ... ,The study was conducted by a team of researchers ... Center Hamburg-Eppendorf. ,As part of the study, ...
... at the Stanford University School of Medicine have identified one ... and treatments for depression converge. Scientists hunt for the ... so many treatments with different mechanisms that the condition remains ... rats the differing mechanisms of depression and its treatment in ...
... of five major breast cancer trials has confirmed that ... improves survival in women with operable HER-2 positive breast ... Dahabreh from the University of Athens reported the results ... 13,000 women whose breast cancer was amenable to surgery. ...
... designed by scientists to be safe to normal tissue but ... preliminary study, researchers said today at the ESMO Conference Lugano ... type of herpes simplex virus modified so that it selectively ... ,It doesnt replicate in normal, healthy cells, so our ...
... An Australian suffered injuries to a thigh and three other ... tourists celebrated the start of the nine-day San Fermin bullrun. ... alcohol and the "encierro", when bulls are released onto the ... (yard) course leading to the arenas where bullfights are later ...
Cached Medicine News:Health News:Researchers Say Brain Region Responsible for Pain's Ability to Seek Attention 2Health News:Brain Pathway for Depression Revealed 2Health News:Brain Pathway for Depression Revealed 3Health News:Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer 2Health News:New Cancer Fighting Virus 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: